Moderna and Merck reported positive Phase III results for their individualized neoantigen mRNA therapy, intismeran autogene (INT), in the INTerpath-001 trial, saying the treatment improved outcomes versus Merck’s Keytruda in melanoma. In a 1,137-volunteer study, the companies reported that intismeran plus pembrolizumab reduced the odds that melanoma would return or spread after surgery, beating Keytruda alone on recurrence-free survival and distant metastasis-free survival. The primary endpoint and key secondary endpoint were both met, according to the disclosure. The market reaction extended beyond the developers to sequencing and diagnostics ecosystems, reflecting how personalized oncology strategies depend on high-throughput tumor analysis and bioinformatics workflows.